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Abstract
Epstein-Barr virus (EBV), an oncogenic gammaherpesvirus, causes acute infectious mononucleosis (AIM) and is linked
to the development of several human malignancies. There is an urgent need for a vaccine that is safe, prevents
infection and/or limits disease. Unique among human herpesviruses, glycoprotein (gp)350/220, which initiates EBV
attachment to susceptible host cells, is the major ligand on the EBV envelope and is highly conserved. Interaction
between gp350/220 and complement receptor type 2 (CR2)/CD21 and/or (CR1)/CD35 on B-cells is required for
infection. Potent antibody responses to gp350/220 occur in animal models and humans. Thus, gp350/220 provides
an attractive candidate for prophylactic subunit vaccine development. However, in a recent Phase II clinical trial
immunization with soluble recombinant gp350 reduced the incidence of AIM, but did not prevent infection.
Despite various attempts to produce an EBV vaccine, no vaccine is licensed. Herein we describe a sub-unit
vaccine against EBV based on a novel Newcastle disease virus (NDV)-virus-like particle (VLP) platform consisting of
EBVgp350/220 ectodomain fused to NDV-fusion (F) protein. The chimeric protein EBVgp350/220-F is incorporated
into the membrane of a VLP composed of the NDV matrix and nucleoprotein. The particles resemble native EBV
in diameter and shape and bind CD21 and CD35. Immunization of BALB/c mice with EBVgp350/220-F VLPs elicited
strong, long-lasting neutralizing antibody responses when assessed in vitro. This chimeric VLP is predicted to
provide a superior safety profile as it is efficiently produced in Chinese hamster ovary (CHO) cells using a platform
devoid of human nucleic acid and EBV-transforming genes.
Keywords: EBV, NDV, VLP, Vaccine, Neutralization
Introduction
Epstein-Barr virus (EBV) is an oncogenic human herpes-
virus [1]. By adulthood, EBV has infected >95% of the
global population. Like all herpesviruses, EBV persists
for life due to a complex life cycle consisting of alternate
latent and lytic phases [1]. In the developing world, pri-
mary EBV infection typically occurs during early child-
hood and is asymptomatic. However, in malaria endemic
regions childhood acquisition poses a heightened risk of
EBV+ Burkitt’s lymphoma [1,2]. In high income coun-
tries primary infection is often delayed [2] resulting in a
syndrome known as acute infectious mononucleosis
(AIM) among 50-77% of adolescents/young adults [3,4].
Although AIM is normally self-limited, illness can be
prolonged. Catastrophic sequelae such as splenic rupture
and hemophagocytosis may be life threatening, and AIM
increases the risk of developing EBV+ Hodgkin lymph-
oma [1,2]. Consistent with its epithelial tropism, EBV is
also highly associated with nasopharyngeal carcinoma
and certain gastric and sporadic carcinomas [1]. Among
healthy individuals, lytic EBV replication is limited and
the pool of latently infected cells remains stable [5]. How-
ever, under conditions of immunosuppression, replication
can accelerate, leading to expansion of EBV-infected cells.
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This increases the likelihood of de novo transformation
of B-cells as seen in EBV+ post-transplant lymphoprolif-
erative disorders (PTLD) and HIV-associated B-cell
lymphomas [6,7]. Uninfected solid organ and stem cell
transplant recipients are particularly susceptible to
developing EBV+ PTLD in settings where preexisting
EBV-specific immunity is lacking [8,9]. To date, disease
management is suboptimal with frequent relapses and
high treatment-related mortality.
Because of its oncogenic potential, options for devel-
oping safe prophylactic and/or therapeutic EBV vaccines
have been limited. The recent success of subunit-based
virus-like particle (VLP) vaccines targeting hepatitis B
and human papillomavirus and their associated tumors
[10,11], suggests a similar strategy could prove success-
ful for EBV. EBV is distinct from other herpesviruses, as
a single antigen, glycoprotein (gp)350/220, is the predom-
inant virion envelope protein [1,12]. Interactions between
EBVgp350/220 and complement receptor type 2 (CR2)/
CD21 and/or (CR1)/CD35 on B-cells is required for cellu-
lar attachment and initiation of latent infection [13-15].
Therefore, gp350/220 is an attractive candidate for devel-
opment of a prophylactic subunit vaccine.
Pre-existing antibodies provide a first line of defense
against many viral pathogens. Much evidence indicates that
neutralizing antibodies targeting gp350/220 are present in
humans, prevent neonatal infection, and are readily gener-
ated in response to immunization of humans and other
animals [16]. Nevertheless, in a Phase I/II clinical trial in
young adults, vaccination with purified soluble recombin-
ant gp350/220 did not prevent infection, although AIM
was reduced [17]. While these observations indicate im-
munity to gp350/220 can limit clinical disease, the variable
success of recombinant soluble protein trials underscore
the historical observation that soluble protein vaccines are
generally limited in immunogenicity [18] and do not
elicit long-term protection. More physiologic presenta-
tion of gp350/220 to the immune system as would occur
on exposure to repetitive units of gp350/220 mimicking
the virion envelope, together with development of a ve-
hicle such as a VLP with potential for recruiting innate
immune cells [19] that robustly stimulate antibody
production might achieve this goal.
In this study, we utilized a novel Newcastle disease
virus (NDV)-based VLP as a delivery platform to display
the gp350/220 ectodomain (ED) in particulate form. Typ-
ical VLPs assemble from one or more viral structural
proteins forming repetitive arrays that resemble native
virus – but usually lack viral nucleic acid [20]. Herein we
report generation of a chimeric EBV-VLP based on
gp350/220 and the NDV-fusion (F) protein (EBVgp350/
220-F). These VLPs are distinct from recently described
complex EBV-VLPs that require assembly in immortal hu-
man cell lines [21], may contain viral DNA/RNA and are
inefficiently produced and released [22]. The chimeric
EBVgp350/220-F VLPs are similar in diameter and shape
to EBV virions and present repeated arrays of gp350/220
on a membranous surface. They are efficiently produced
and released from non-human cell types such as Chinese
hamster ovary (CHO), a Federal Drug Agency (FDA)
approved vehicle. Immunization of BALB/c mice with
EBVgp350/220-F VLPs without adjuvant elicited strong
and long lasting neutralizing antibody responses able to
block EBV infection in vitro.
Materials and methods
Virus
B95-8 strain EBfaV-GFP was provided by Richard
Longnecker (Northwestern University, Chicago). EGFP-
EBV was prepared as described [23]. Kaposi’s sarcoma
herpesvirus (KSHV) and EBV-EGFP from the AGS line
were gifts from Christine King (SUNY Upstate Medical
School) and Liisa Selin (University of Massachusetts
Medical School), respectively.
Cell lines
293A, a clone of 293 (human embryonic kidney) was
from Life Science Technologies. 293 T, a 293 derivative
expressing SV-40 T antigen, CHO, Vero (African green
monkey kidney), ELL-0 (chicken embryo), K562 (human
erythroleukemia), Raji (EBV+ Burkitt’s lymphoma), HB168
(72A1 murine hybridoma) were from the American Type
Culture Collection. 293A, CHO, and ELL-0 were cultured
in DMEM. Other lines were grown in RPMI media. All
media contained 1% L-glutamine, 10% heat-inactivated
fetal bovine serum (FBS) and 2% penicillin-streptomycin.
Plasmid vectors
Full length EBVgp350/220 (BLLF1) isolated from the
BamHI L fragment of B95-8 [24] by PCR was cloned
into pCAGGS [25]. An upstream primer containing a
SalI restriction enzyme site and a Kozak sequence: For-
ward Primer: 5′- AAC ATA GCT GAC GCC ACC ATG
GAG GCA GCC TTG CT -3′ together with a down-
stream primer that incorporated a double stop followed
by a NruI site: Reverse Primer: 5′- TTG ATA TCG CGA
CTA TTA TTA TAC ATA GGT CTC GG -3′ was used.
After amplification, the PCR product was digested with
SalI and NruI, purified and ligated into pCAGGS pre-
digested with XhoI and MscI. Fidelity was confirmed by
DNA sequencing.
pCAGGS-EBVgp350/220-F
A chimeric fragment consisting of nucleotides encoding
gp350/220 ectodomain (ED), amino acids 1–864, fused
to the NDV-F heptad repeat 2 (HR2), transmembrane
(TM) and cytoplasmic (CT) domains, amino acids 466–
553, was constructed by three-way ligation (EBVgp350/
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220-F). A PCR product containing the gp350/220 ED
was digested with SalI and ScaI. A PCR fragment encod-
ing the NDV-F membrane proximal HR2 domain, TM
and CT domains in addition to adjacent pCAGGS vector
sequences was PCR amplified from pCAGGS-F [26]
incorporating a ScaI site upstream and a HindIII site
downstream. Forward Primer: 5′- AAC ATA AGT ACT
GCT TGG GAA TGT CAA CAA CTC G -3′ and Re-
verse Primer: 5′- TAC GCC AAG CTT GGG CTG
CAG GTC GAG GGATCT CCA -3′. This isolated F frag-
ment was cut with ScaI and HindIII. The pCAGGS vector
was digested with XhoI and HindIII and gel-purified. The
three respective DNA fragments were co-incubated in a
5:5:1 ratio with T4 DNA ligase generating pCAGGS-
EBVgp350/220-F. Fidelity was confirmed by DNA sequen-
cing. pCAGGS-F, pCAGGS-M and pCAGGS-NP derived
from NDV (Avulavirus) have been described [26].
Transfection, generation and purification of gp350/220-F
VLPs
1.0 μg/well of pCAGGS, pCAGGS-gp350/220 wildtype
(WT) or pCAGGS-EBVgp350/220-F were individually
transfected into 80% subconfluent CHO, 293A, Vero and
ELL-0 cells seeded in six-well tissue culture plates using
Lipofectamine and Reagent Plus (Life Sciences Technolo-
gies) according to the manufacturer’s direction. Cells were
harvested at 48 h post-transfection to assess surface
expression of gp350/220 by cytometry.
Small-scale and large-scale VLP stocks were prepared
as outlined [27]. For large-scale preparation, equal amounts
(8 μg/plasmid) of pCAGGS-NDV-M, −NP and pCAGGS-
EBVgp350/220-F plasmids were co-transfected into cells
seeded in T-175 cm2 flasks. DNA-Lipofectamine com-
plexes were incubated at 37°C for 5 h with 293 T and ELL-
0 or overnight with CHO cells. Complexes were removed
by washing and 20 ml of complete media was added. For
some preparations 20 ml of complete media containing
4 mM of sodium butyrate (Millipore ED) and 20 ng/ml of
TPA (12-O-tetradecanonylphorbol 13-acetate) (Sigma)
was added as chemical induction had been reported to
increase production of HIV VLPs [28], but the above
addition did not significantly alter VLP yield in our
hands. Eleven flasks were seeded for each large-scale
preparation. VLPs were isolated by sedimentation and
sucrose gradient purification [27].
Antibodies
Primary: Monoclonal antibodies (mAb)-72A1 and -2 L10
anti-gp350/220 were from EMD Millipore. Polyclonal
rabbit anti-NDV and anti-HR2 have been described [29].
MAb anti-CD35 (clone E11) and anti-CD21 (clone LT21)
were from BioLegend.
Secondary: Horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG (total and isotype specific) antibodies
or goat anti-rabbit antibodies for immunoblot or ELISA
were from Sigma. Goat F(ab’)2 anti-mouse IgG (H + L)
AF488 or AF594 was used for cytometric and confocal
analyses (Invitrogen). Goat anti-mouse IgG (H + L) immu-
nogold was used for electron microscopy (EM) (Aurion).
Biochemical analysis
Purified EBV, VLPs or cells were lysed in RIPA buffer
(Boston Bioproducts) containing a complete protease in-
hibitor cocktail (Roche Applied Science). Lysates were
incubated for 15 min on ice, microcentrifuged for 5 min
at 10,000 rpm and the protein content of each lysate deter-
mined by Bradford assay. Lysates were boiled for 5 min in
Laemmli SDS-sample buffer (Boston Bioproducts) under
non-reducing conditions. 10 μg of lysate was loaded onto a
4–12% polyacrylamide gel for protein separation. Protein
bands were detected by Pierce’s silver stain kit according to
the manufacturer’s recommendation. For immunoblot,
proteins were transferred to a PVDF membrane using iblot
(Life Sciences Tech.). Membranes were blocked with 5%
non-fat dry milk (LabScientific) for 30 min and detected
with specific antibodies as described in Results.
Immunogold analysis (EM)
VLPs and viruses were analyzed by EM as described
[30]. Purified particles were dialyzed against 1 L of TNE
(100 mM Tris; 2.0 M NaCl; 10 mM EDTA; pH 7.4) to
remove residual sucrose, incubated with 3% bovine serum
albumin (BSA) in TNE for 45 min. and embedded on a
grid. A 1:40 dilution of mAb-72A1 (10 ug/ml) in 1% BSA/
TNE was added to the grid for 1 h at RT, washed and the
grid re-incubated with gold-conjugated anti-mouse IgG
for 1 h. After two final washes, the grid was negatively
stained with 12% phosphotungstic acid (pH 7) for 15 sec,
air dried for 30 min and examined using a Tecnai trans-
mission electron microscope (FEI).
Binding assays, confocal microscopy and cytometry
Confocal microscopy was performed as outlined [14]. 106
cells seeded onto Labtek slides were incubated at RT for
1 h with uniform amounts of VLP pre-determined by
silver stain and/or Bradford assay. Mixtures of cells and
VLPs were first stained with anti-CD21, anti-CD35 or
isotype control for 30 min on ice, washed 2x and re-
incubated with AF594-goat anti-mouse antibodies, washed
and further stained with AF488-coupled-mAb-2 L10 for
30 min on ice. Nuclei were stained with DAPI 33342
(Sigma) for 5 min at RT. Cells were finally washed 2x,
mounted with Mounting Medium (DakoCytomation)
and imaged with an UPlanApo 60x1.42 NA objective on
an Olympus BX62 microscope fitted with a cooled
Hamamatsu Orca AG CCD camera. Microscope, filters,
and camera were operated as outlined [31]. Deconvolution
was as described [14].
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To analyze cell surface gp350/220 expression, cells
transfected with relevant plasmids were suspended in
PBS 2% heat-inactivated FBS, washed twice with PBS,
incubated with anti-gp350/220 (mAb-72A1), washed
twice, re-incubated with goat anti-mouse-AF488 and re-
washed. Cytometric analysis was performed on a FACS-
can or LSRII benchtop FC (Becton-Dickinson). Data
were analyzed using CellQuest Pro Version 4.0.1 (B-D)
and/or FlowJo Cytometry software (Tree Star Inc). A
minimum 10,000 events was recorded for each analysis.
Experiments were repeated 3x.
Immunization
Groups of five 6–8 week BALB/c mice (Jackson Labora-
tories) were immunized intraperitoneally with 10 μg
EBVgp350/220-F VLP, soluble recombinant EBVgp350/220
ED protein (amino acids 4–863; Immune Technology)
(positive control), or UV-inactivated EGFP-EBV (UV-EBV)
(positive control). UV-inactivation was achieved by expos-
ure to 254 nm UV light for 5 min (source model UVG-11,
UVP) from a distance of 10 cm, producing complete loss
of EGFP expression upon EBV-superinfection of Raji (see
below). Gp350/220 content of the respective immunogens
was normalized by silver stain. Immunogens were re-
suspended to a final volume of 0.5 ml in TNE 10% sucrose
or in 10% sucrose TNE buffer alone (vehicle control). Mice
were boosted with equal amounts of antigen on days 43,
172, 183 and 218. After primary immunization, tail vein
serum was obtained at two-week intervals until day 84,
then again on days 154, 186, and 197. A terminal bleed
was performed on day 228. Long-term antibody titers
and neutralization were first assessed on day 56 to
optimize the neutralization assay (data not shown).
Thereafter neutralization was assessed with serum ob-
tained at day 154 or 111 days after a single boost on day
43. Subsequently, three additional immunizations were
administered on days 172, 183 and 218. All time points
were used to determine anti-gp350/220 specific IgGs.
Following the final boost mice were sacrificed on day 228
to again obtain sera for determination of anti-gp350/220
neutralization assays that followed a four-boost regimen.
TNE served as a negative control. Experiments were re-
peated at least twice. Animal procedures were performed
in accordance with the University of Massachusetts Med-
ical School IACUC and Institutional Biosafety Committee.
Enzyme-linked Immunosorbent Assay (ELISA)
IgG titers were measured by ELISA [32] using soluble
gp350/220 ED as target antigen. Briefly, 96-well microti-
ter plates (Nunc-Immuno Plate Maxisorp) were coated
with 50 ng/well of recombinant gp350/220 ED in a car-
bonate buffer (pH 6.2) at 4° C overnight and blocked with
1% BSA. Serially diluted sera in PBS was added for 2 h at
RT and washed. Antibody binding was detected with
HRP-labeled goat anti-mouse IgG, IgG1, IgG2a, IgG2b
and IgG3 secondary antibodies at RT for 1 h. Plates were
washed 5x and the substrate tetramethylbenzidine (Life
Science Technologies) was added. Reactions were stopped
with 2 M sulfuric acid. To determine antibody titer, optical
density was read at 450 nm with an ELISA reader
(Spectramax® Plus 384, Molecular Devices). The highest
antibody dilution yielding an OD450 2x higher than that of
TNE-treated mice was designated the endpoint titer.
Anti-gp350/220 mAbs served as positive controls.
Neutralization studies
Day 154 sera from mice that had received a single
booster on day 43 and day 228 sera (terminal) from mice
serially immunized with EBVgp350/220-F VLP, UV-EBV,
soluble gp350/220 ED and TNE were heat-inactivated at
56°C to remove complement. Sera were then diluted as
described and then pre-incubated 1:1 with purified EGFP-
EBV at different concentrations (typically 5 or 10 microli-
ters of a 1:5 virus dilution from a single frozen stock) for
1 h at RT before infecting 105 Raji cells seeded in 24-well
tissue culture plates as previously outlined [23,33]. Anti-
gp350/220 mAb-72A1 (neutralizing), mAb-2 L10 (non-
neutralizing) and sera from TNE-treated mice (vehicle)
served as controls. Experiments were repeated at least 3
times. Plates were incubated at 37°C for 3 days and visual-
ized daily to enumerate GFP+ cells. Cytometry was per-
formed on day 3 for end-point analysis.
Statistical analysis
Neutralization data were analyzed using Graph Pad Prism
6 Software (GraphPad Software, Inc., San Diego). The dif-
ference between neutralizing antibody titers of immunized
and non-immunized (TNE-vehicle control) mice was de-
termined using the unpaired two-tailed t test for inde-
pendent groups. Statistical significance of the tests was
based on two-sided p values ≤ 0.05.
Results
Detection of chimeric EBV-gp350/220-F on the surface of
mammalian and avian cell lines
VLPs assemble from three or four virion proteins, the
envelope glycoproteins, F (fusion, a type 1 glycoprotein)
and/or HN (hemaglutinin-neuraminidase, a type 2 glyco-
protein), together with core proteins M (matrix) and NP
(nucleocapsid protein) that drive assembly and release
[27,34]. Recently it was demonstrated that the ability to
form VLPs is preserved when the ED of F is substituted
with an ED derived from unrelated viral envelope type 1
proteins as long as the TM and CT of F remain intact
[35]. To generate EBVgp350/220 bearing VLPs, we first
constructed an EBVgp350/220-F chimeric plasmid by fus-
ing the nucleotide sequences encoding amino acids that
comprise the entire ED of EBVgp350/220 to sequences
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encoding NDV-F HR2, TM and CT (Figure 1A). To assess
whether the expressed chimera appropriately localized
to the plasma membrane, pCAGGS-EBVgp350/220-F
and pCAGGS-EBVgp350/220 WT plasmids were indi-
vidually transfected into cell lines from four different
species (CHO, ELL-0, Vero and 293A). Membrane ex-
pression of the gp350/220 ED was analyzed by cytome-
try. MAb-72A1 directed to the N-terminal attachment
epitope of gp350/220 [36] detected expression of both
gp350/220 WT and chimeric EBVgp350/220-F proteins
at the surface of all relevant transfectants (Figure 1B).
Anti-gp350/220 mAb-2 L10 [36] that recognizes a dis-
tinct epitope likewise detected gp350/220 surface ex-
pression (not shown). Comparative expression of WT
gp350/220 and chimeric EBVgp350/220-F, within each
transfected line, did not significantly differ. Gp350/220
was not detected in cells transfected with an empty
pCAGGS vector (negative control).
Figure 1 Construction and expression of EBVgp350/220-F chimeric protein. (A) Diagram of full length EBVgp350/220-WT (top), full length
wild type NDV-F (middle), and chimeric EBVgp350/220-F (bottom) (not to scale). C-terminal amino acid sequences comprising the gp350/220
ectodomain (ED) and N-terminal sequences from NDV-F HR2 at the point of fusion are indicated. The bolded black line represents amino acid
sequences deleted in frame in the gp220 isoform. Both isoforms contain the N-terminal B-cell attachment epitope. (B) Expression of EBVgp350/
220-WT and EBVgp350/220-F on the surface of four cell lines (CHO, ELL-0, Vero and 293A). 106 cells from each line were transfected with 1 μg
of pCAGGS-EBVgp350/220 WT, pCAGGS-EBVgp350/220-F or pCAGGS alone (vector control). At 72 h post-transfection, cells were stained with
anti-gp350/220 mAb-72A1 followed by AF488-coupled goat anti-mouse IgG (H + L) and analyzed by flow cytometry.
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Assembly and characterization of chimeric EBVgp350/
220-F VLPs
Following confirmation of plasma membrane expression,
as required for particle assembly, pCAGGS-EBVgp350/
220-F was co-transfected with NDV core proteins M and
NP into different cell lines to generate chimeric VLPs
as diagramed in Figure 2A. Particles from distinct
preparations released into cell supernatants were puri-
fied as outlined [27], lysed and protein analyzed by
immunoblot using either anti-gp350/220 (mAb-72A1),
polyclonal rabbit anti-NDV HR2 or anti-NDV (entire
virus) (Figure 2B) for detection. To confirm the specificity
of chimeric VLP formation and antibody recognition, a
series of control experiments were performed to document
Figure 2 Assembly and characterization of EBV-gp350/220-F VLPs. (A) Schematic diagram showing cDNAs pCAGGS-NDV-M, −NDV-NP and
-EBVgp350/220-F co-transfected into cells followed by VLP assembly and release. (B) Supernatants containing independent EBV-VLP preparations
were harvested daily between 24–96 h, concentrated and purified by sucrose-gradient centrifugation followed by particle lysis and immunoblot.
mAb-72A1 anti-gp350/220 (left two panels), polyclonal anti-HR2 (third panel) and polyclonal anti-NDV (right panel) detected EBVgp350/220 ED
and NDV-F C-terminal peptides respectively. Anti-NDV also detected M and NP in VLPs and NDV, but not EBV. Lanes 1–3 contain VLPs derived
from 293T, lanes 6,7,10,11,14, 15 from CHO cells. Lysates of purified EBV (lanes 4, 8, 12, 16) and NDV (lanes 5, 9, 13) were controls. (C) Different
combinations of pCAGGS plasmids encoding F, M, NP, gp350/220 and gp350/220-F as indicated were co-transfected into 293T cells. Supernatant
content was pelleted and analyzed by immunoblot using anti-gp350/220 and anti-HR2 antibodies. Lane 1: NDV-VLP (NP, M, F), lane 2: NP, M,
lane 3: NP, M, gp350/220 WT, lane 4: EBV-VLP (NP, M, EBVgp350/220-F), lane 5: M, EBVgp350/220-F, lane 6: pCAGGS . Both antibodies in lane 4
alone detected bands of the expected MW, indicating a chimeric EBV-VLP was specifically assembled and released. (D) Electron micrograph of
negatively stained sucrose gradient purified EBVgp350/220-F VLPs prepared in CHO cells compared with native EBV -/+ immunogold-coupled
antibodies. Top, structure and size of the chimeric VLP compared with EBV without antibody. Middle, demonstration that mAb-72A1 detected by
immunogold-coupled goat anti-mouse IgG binds the surface of a chimeric EBVgp350/220-F VLP and EBV (control). Bottom, but not a chimeric
KSHV-VLP or KSHV. (E) Silver stain of increasing amounts of purified chimeric VLPs released from ELL-0 cells compared with NDV. Positions of
EBVgp350/220-F, NDV-NP and -M are indicated by arrows. MW markers are at left.
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that classical requirements for NDV-VLP assembly were
met. Different combinations of pCAGGS plasmids encod-
ing NDV-F, −M, −NP, EBVgp350/220-WT, EBVgp350/220-
F as shown in Figure 2C were co-transfected into 293 T
cells and the putative particles purified as previously
described followed by immunoblot (Figure 2C). Chimeric
VLPs expressing EBVgp350/220-F were detected with anti-
gp350/220 (top panel) antibody only in cells co-transfected
with EBVgp350/220-F, −M and -NP (lane 4), but not in
cells transfected with F-M-NP (lane 1), M-NP (lane 2),
EBVgp350/220-WT, −M-NP (lane 3), EBVgp350/220-F and
-M (lane 5) or pCAGGS alone (lane 6). Anti-HR2 antibody
detected the assembled chimeric VLP in lane 4 as well as a
WT NDV-VLP in lane 1 (not shown) demonstrating that
criteria for VLP formation were satisfied.
To further determine whether incorporation of
EBVgp350/220-F into VLPs led to formation of parti-
cles similar in size and overall shape to the native
virus, purified VLPs were compared to EBV by negative
staining and immunogold-conjugated antibody analysis.
Figure 2D top shows that purified VLPs containing
EBVgp350/220-F were approximately 100 nm in diameter,
similar to the diameter of typical EBV virion membranes,
though they were less uniform in shape [37]. MAb anti-
gp350/220 (72A1) detected with gold conjugated anti-
mouse Ig bound the outer surface of both native EBV and
the chimeric VLPs, indicating gp350/220 was expressed
on the respective envelopes (Figure 2D, middle). Neither
mAb-72A1 nor the gold-conjugated secondary antibody
bound a KSHVK8.1-derived VLP (J.G.O. manuscript in
preparation) or the KSHV envelope (Figure 2D, bottom)
confirming the specificity of antibody recognition. The
purity of the chimeric VLP compared with NDV and the
uniformity of EBVgp350/220-F protein expression on
chimeric VLPs was independently analyzed by silver
stain (Figure 2E) alternatively revealing the content of
these particles.
Visualization of EBVgp350/220-F VLP attachment to CD21
and CD35 bearing cells
EBVgp350/220 binds CD21 and/or CD35 on human cells
[13,14]. To determine whether chimeric VLPs expressed
from CHO cells retained the receptor-binding specificity
of the virion envelope protein, we incubated EBVgp350/
220-F VLPs with Raji, a latently EBV-infected B-cell line
that naturally expresses high amounts of CD21 [13] and
can be superinfected with EBV. In addition a panel of
receptor negative cell lines, Nalm6 and K562 (not shown),
together with their CD21 or CD35 transfectant sublines
was investigated [14]. Receptors (red) and VLPs (green)
were visualized by indirect immunofluorescence using a
confocal microscope for detection. As shown in Figure 3,
whereas chimeric VLPs abundantly bound Raji, no attach-
ment to Nalm6 was detected. Nalm6CD21, Nalm6CD35,
K562CD21 and K562CD35 all bound EBVgp350/220-F
VLPs. Moreover, in each of the receptor bearing sub-
lines, the chimeric VLPs (green) co-localized (yellow)
with the relevant cell surface receptor (Figure 4, two
right columns).
Development of specific IgG responses to EBVgp350/220
in BALB/c mice immunized with EBVgp350/220-F VLPs
To determine whether chimeric VLPs elicit EBVgp350/
220 specific antibody responses, mice were immunized
intraperitoneally with 10 μg of EBVgp350/220-F VLP de-
rived from CHO cells. UV-EBV and soluble gp350/220
ED served as positive controls and TNE as vehicle con-
trol. Equivalence of gp350/220 protein content among
the different immunogens was determined by silver stain
(not shown). All animals received booster immuniza-
tions on days 43, 172, 183 and 218. Sera were collected
two weeks post-boost. None of the animals displayed
signs of local or systemic inflammation or changes in
feeding or body weight that would indicate toxicity.
Soluble recombinant gp350/220 ED served as the target
antigen in an IgG ELISA (Methods). Anti-gp350/220
specific total IgG antibody titers significantly increased
among mice immunized with the chimeric VLP, UV-EBV
and soluble recombinant gp350/220 ED compared with
pre-vaccination and control titers (Figure 4). Historical
controls using NDV-F VLPs as immunogen were non-
reactive in gp350/220-based ELISAs (not shown). The
increase in EBV-gp350/220 specific antibody appeared to
plateau on day 84 after the initial boost, but then further
increased after the second and third boosts. There was a
significant difference in antibody titers of mice immunized
with UV-EBV, compared with soluble gp350/220 ED and
EBVgp350/220-F VLP, although the slopes of the response
curves were similar. Gp350/220 specific antibody was
absent from TNE-immunized mice. All gp350/220-based
immunogens produced long-term gp350/220-specific re-
sponses, though mice immunized with native EBV (UV-
EBV) maintained significantly higher titers of gp350/220
antibody compared to mice immunized with VLP or
soluble recombinant protein.
EBV-gp350/220 VLPs induce a dominant IgG1 subclass
response
To uncover the composition of IgG responses, we com-
pared the subclass frequency of IgG antibodies induced
by immunization with EBVgp350/220-F VLP, UV-EBV
and recombinant soluble gp350/220 ED (Figure 5). IgG1
antibody, which typically reflects a T-helper type 2 re-
sponse [38], was the most abundant subclass among mice
irrespective of the gp350/220 immunogen. IgG1 responses
uniformly increased over time when analyzed on days 14,
56, 154 and 228 post-immunization (Figure 5A). In con-
trast, titers of IgG2a, IgG2b and IgG3 did not significantly
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change or diminished over time. While IgG2a titers also
appeared to trend upwards among mice immunized with
UV-EBV (Figure 5B), (though to a 10-fold lesser degree
than IgG1 titer) coordinate detection of IgG2a responses
among the TNE-immunized control group in this assay
alone (compare 5A, C, D) raised concern that the specifi-
city of this reagent was compromised. A transient acute
rise in IgG2b titers that accompanied primary chimeric
VLP immunization did not persist.
Anti EBV-gp350/220 antibodies generated following VLP
immunization neutralize EBV infection in vitro
It is well known that titer is not the sole gauge of a pro-
tective antibody response, as certain immunogens can
induce antibodies that promote, rather than block infec-
tion and high affinity blocking antibodies can be highly
effective at low titers [39]. To evaluate the ability of anti-
bodies generated in response to chimeric EBV-VLP, UV-
EBV and soluble recombinant gp350/220 ED to block
Figure 3 Purified EBVgp350/220-F VLPs bind CD21 and CD35. (A) Raji (positive control), Nalm6 (negative control) and CD21 or CD35
transfected sublines of (A) Nalm6 and (B) K562 were characterized and prepared as described [14]. First, the respective complement receptors
were stained with primary mAbs followed by AF594-coupled goat Fab’2 anti-mouse IgG (red). Attachment of EBVgp350/220-F VLPs was next
detected directly with AF488-coupled anti-gp350/220 (mAb-2 L10)(green) that recognizes an epitope distal to the attachment site. Cell content
was documented by nuclear staining with DAPI. Sequential confocal images showed that the chimeric VLP binds to CD21 or CD35 bearing cells
whereas no binding to receptor negative Nalm6 cells was seen. Visualization of 3D merged images confirmed extensive co-localization (yellow) of
the chimeric VLPs with both CD21 and CD35.
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infection, we assessed the in vitro neutralizing antibody
titers of sera collected (1) on day 154 (111 days after a
single boost) and (2) on day 228 (terminal bleed col-
lected 10 days after a fourth boost). Because EBV does
not plaque and large virus quantities are difficult to ob-
tain, EBV was first titered by the Raji cell infection assay
(Figure 6A). Different amounts of a frozen stock of
EGFP-EBV (0, 2.5, 5, 10 microliters) were incubated with
Raji in the absence of serum. After infection with 10 μl of
stock EGFP-EBV ‵80% of Raji cells reproducibly fluo-
resced upon detection by cytometry whereas 5 μl of stock
EGFP-EBV reproducibly resulted in ~ 50% fluorescence
(Figure 6A). When 10 μl EGFP-EBV was pre-incubated
1:1 with serial dilutions (1:3, 1:9, 1:27) of non-neutralizing
mAb-2 L10 or TNE control sera fluorescence dropped
to ~50% of infected Raji cells (Figure 6B). In contrast
when serially diluted sera from mice immunized with
EBVgp350/220-F VLPs, UV-EBV or soluble recombin-
ant gp350/220 ED was likewise pre-incubated with
EGFP-EBV, infection was significantly reduced in a dose
dependent manner compared to TNE-immunized sera
(Figure 6B). Purified mAb-72A1 (positive control) con-
taining only IgG1 antibody directed to the gp350/220
attachment epitope was most effective at neutralization.
Use of serial dilutions confirmed the specificity of the
neutralizing antibody response.
In a second set of experiments neutralizing antibody
was measured at the time of sacrifice ten days after a
pre-terminal boost. When 5 μl EGFP-EBV was pre-
incubated 1:1 with irrelevant mouse serum, further dilut-
ing virus, fluorescence dropped to ~25% of infected Raji
cells (not shown). As predicted, pre-incubation of EGFP-
EBV 1:1 with serum from TNE treated mice (negative
control) produced ~ 27% fluorescence of Raji (Figure 6C)
as did pre-treatment with the non-neutralizing anti-
gp350/220 mAb-2 L10. In contrast when terminal sera
from mice immunized with EBVgp350/220-F VLPs or
UV-EBV was pre-incubated with EGFP-EBV, infection
was reduced in comparison with TNE-immunized sera:
15% (p = 0.0217) and 5% fluorescent cells (p = 0.0002)
(Figure 6C) respectively. As expected, purified mAb-72A1
(positive control) was most effective at neutralization (1%
fluorescent cells, p = <0.0001 compared with TNE). Anti-
bodies generated after immunization with soluble recom-
binant gp350/220 ED were least effective (22% fluorescent
cells, p = 0.0298 versus TNE). Though the numbers are
small, the comparative ability of antibodies generated in
response to immunization with chimeric VLP versus UV-
Figure 4 Long-term IgG anti-gp350/220 antibodies are generated in mice immunized with EBVgp350/220-F VLPs, UV-EBV and soluble
recombinant gp350/220 ED. Groups of five mice were immunized intraperitoneally with either EBVgp350/220-F VLPs (green line), UV-EBV (red
line) or soluble recombinant gp350/220 ED (purple line). Each immunogen contained equivalent amounts of gp350/220. TNE served as vehicle
control (blue line). All immunizations were performed in the absence of adjuvant. Anti-gp350/220 IgG titers were determined over time up to
day 228. Booster immunizations were performed on days 43, 172, 183 and 218 as indicated on the time line (bottom). Primary and booster
vaccinations contained equivalent immunogen. Specific anti-gp350/220 ED titers were determined by ELISA (Methods). X-axis shows the day on
which serum was obtained for ELISA. Y-axis displays anti-gp350/220 antibody titer on a log scale. Vertical lines indicate the average titer produced
by groups of five mice at the time of serum collection and associated error bars indicate the standard deviation.
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EBV to neutralize EBV infection of Raji cells was not
significant (p = 0.2188).
Discussion
Based on emerging evidence of the spectrum of EBV-
associated diseases, Anthony Epstein first made a call for
development of an EBV vaccine in 1976 [40]. To date,
there is no licensed vaccine that prevents infection, AIM
or any of the EBV-associated cancers. Because of the
oncogenic potential of EBV, options for developing a
safe, prophylactic and/or therapeutic EBV vaccine remain
challenging. Similar to HSV1 replication defective vaccine
candidates [41], EBV DNA packaging mutants [21] and
disabled virions that lack the major oncoproteins [22] have
appeal because of the multiplicity of potential immuno-
gens present. However, incomplete knowledge of virion
protein functions, concern about inadvertent association
of oncogenic DNA/RNA fragments with assembled vi-
rions, limited production and release of virus, as well as
current requirements for propagation in transformed hu-
man cell lines suggest such candidates may prove unable
to meet stringent FDA safety guidelines. Additional con-
cerns have been raised about EBV proteins expressed from
replicating virus vectors such as Vaccinia or attenuated
Measles [42] - the advantage and disadvantage being
propagation of EBV-encoded nucleic acids and protein.
Although vaccinia-based introduction of EBV vaccine tar-
gets, especially potential oncoproteins may be appropriate
in patients with incurable tumors [43], current recombin-
ant vaccinia vaccines are regarded as high risk because of
frequent side effects even among healthy individuals. EBV
capsids assembled from recombinant proteins expressed
Figure 5 Comparative analysis of IgG subclass responses to vaccination with EBVgp350/220 containing immunogens: EBVgp350/220-F
VLPs, UV-EBV and soluble recombinant gp350/220 ED. Serum IgG subclass titers were determined on days 14, 56, 154 and 228 post-vaccination
by gp350/220 ED-based ELISA. Immunizations were carried out as described in Figure 4. TNE was the vehicle control. X-axis displays immunogen and
date of vaccination. Y-axis indicates antibody titer specific for soluble recombinant gp350/320 ED on a log scale (A) IgG1 (B) IgG2a (C) IgG2b (D) IgG3.
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in insect cells have also been described as a potential
vaccine candidate and would present repetitive antigen
to the immune system [44]. However, at present their
safety and their efficacy as neutralization targets remains
to be documented.
EBVgp350/220 is the most abundant glycoprotein on
the virus envelope and is the primary target of neutraliz-
ing antibodies following natural infection. Gp350/220
has long been a major focus of vaccine trials [16]. To
date, vaccinia viruses expressing soluble recombinant
Figure 6 Neutralization of Raji cell infection upon pre-incubation with antibodies generated following EBV-VLP immunization. (A)
Infection assay. Because EBV does not plaque, infectivity of EGFP-EBV from a frozen stock was directly quantitated by cytometry. Ten microliters
stock virus in the absence of serum yielded ~80% infection (green fluorescence) 73 h after infection of Raji and was selected for neutralization
experiments performed 111 days after the initial boost. Five microliters stock virus without serum yielded ~50% infection (green fluorescence) 73 h
after infection of Raji and was used for terminal neutralization experiments. (B) Day 111 (long-term) Neutralization Assay. Pooled sera from groups
of five BALB/c mice immunized with EBVgp350/220-F VLP, UV-EBV, soluble recombinant gp350/220 ED or TNE (vehicle control) were serially
diluted as indicated and then pre-incubated with EGFP-EBV to assess neutralization (Methods). Infected cells were incubated at 37°C for 72 h at
which time EGFP+ Raji cells were enumerated by cytometry. X-axis, neutralizing antibody source and dilution; Y- axis, percent EGFP+ Raji cells
post-infection. (C) Terminal Neutralization assay. Pooled terminal bleed sera from groups of five BALB/c mice immunized with EBVgp350/220-F
VLP, UV-EBV or soluble recombinant gp350/220 ED were pre-incubated with EGFP-EBV to assess neutralization (Methods). Infected cells were
incubated at 37°C for 72 h at which time EGFP+ Raji cells were enumerated by cytometry. X-axis, neutralizing antibody source; Y-axis, percent
EGFP+ Raji cells post-infection. Terminal sera or mAb controls were pre-incubated 1:1 with EGFP-EBV causing further virus dilution such that
~25% of Raji cells were maximally infected (fluoresced green) when pre-incubated with non-blocking mAb-2 L10 or TNE. Pre-incubation with
mAb-72A1 (neutralizing) served as the positive control. Results are expressed as mean ± standard deviations (SD). Horizontal black lines
terminating in short vertical lines compare sets of neutralization experiments with 2-sided p-values indicated above the line.
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gp350/220, attenuated measles virus expressing soluble
recombinant gp350/220, truncated tetramers of the
gp350/220 ED [45] as well as purified soluble gp350 pro-
tein have been evaluated to varying degrees either in ani-
mal models or in humans. However, controlled human
Phase I/II clinical trials in which the immunogen was
adequately characterized and in which efficacy could be
statistically assessed remains limited. A three-dose regi-
men of purified soluble recombinant gp350 purified
from CHO cell supernatants together with adjuvant was
safe and immunogenic in healthy adults 18–25 years old
residing in Europe [46], and in children scheduled for
renal transplant [47]. Immunization induced gp350 spe-
cific neutralizing antibodies in the young adult group
and provided protection from symptoms of AIM, how-
ever, EBV infection was not prevented [17]. The overall
variable success of recombinant soluble protein trials
underscores the historical observation that protein sub-
unit vaccines generally display limited immunogenicity
[18,19], and are not optimal for eliciting long-term pro-
tection. We reasoned that more physiologic presentation
of gp350/220 to the immune system as would occur on
exposure to the repetitive units of gp350/220 displayed
on the virion envelope might achieve robust protective
humoral as well as cell-mediated responses.
In this study we described development of a candidate
chimeric EBV VLP vaccine with the potential to satisfy
safety requirements and overcome limited immunogen-
icity. The synthesis, assembly, biological properties and
humoral immune responses to this immunogen were
characterized. First we showed that following transfection
of cDNA encoding the chimeric glycoprotein, the gp350/
220 ED was well expressed on the surface of diverse cell
lines including CHO, 293, Vero and ELL-0 (a prerequisite
for VLP assembly). Next we documented that after co-
transfection of relevant cDNAs, VLPs assembled and were
efficiently released into CHO supernatants. Demonstra-
tion of production in CHO was significant, as over two-
thirds of recombinant therapeutic agents on the market
are generated in CHO cell lines [48] that grow to high
density in suspension and without FBS. Furthermore, no
adventitious viral product, a major concern to regulatory
authorities has been reported for CHO cells, in contrast to
cell lines of human origin [49].
Subsequent analysis of the gradient purified chimeric
VLPs by silver stain, immunoblot, and EM revealed that
they were intact, pure and that the gp350/220 ED could
be detected by distinct anti-gp350/220 mAbs. This sug-
gested that the conformation of the attachment site was
conserved and that some more distal portions of the ED
were likely physiologically folded. The binding mecha-
nisms used by native virus appeared to be retained as
chimeric VLPs bound cells expressing the attachment
receptors CD21 and CD35 and co-localized with each of
these receptors. EM further revealed that chimeric VLPs
resembled native EBV in their morphology and diameter,
and immunogold staining revealed gp350/220 protein on
the VLP surface.
EBV is a strictly human virus. Lack of an EBV vaccine
is in part due to the paucity of robust in vivo models for
studying EBV pathogenesis [50,51]. To begin to investi-
gate the immunogenicity of EBVgp350/220-F VLPs, with
a goal towards establishing efficacy in models such as
humanized rodents, we immunized BALB/c mice with
VLPs, UV-EBV or soluble recombinant gp350/220. No ad-
juvant was used in any of these experiments. We deter-
mined both the specific antibody titer and the ability of
the antibodies to neutralize EBV infection in vitro. Total
IgG anti-gp350/220 in sera of chimeric VLPs, UV-EBV
and soluble recombinant gp350/220 slowly increased over
time after primary immunization until day 43 at which
time a first booster was administered. Following the boost,
antibody titers rapidly rose among animals immunized
with gp350/220 protein, peaking at day 56. No gp350/220
specific IgG antibody was detected in control mice (TNE).
All anti-gp350/220 immunized mice developed long-term
neutralizing antibody responses that were present 111 days
after a single boost and were detected following additional
boosts at the time of sacrifice on day 228.
Although antibody titers and virus neutralization was
highest among groups of mice immunized with UV-EBV
compared to EBVgp350/220-F VLP, several factors may
account for this observation and point to specific methods
for optimizing chimeric VLP immunogenicity. Whereas
the equivalence of total gp350/220 protein content was
established in the three experimental groups prior to
immunization, UV-EBV was less highly purified than the
chimeric VLPs raising the possibility of low-level con-
tamination with environmental adjuvants that enhanced
antibody responses. The potential contribution of dis-
tinct adjuvants to VLP immunogenicity will be assessed
in future experiments. A unique density or distribution
of gp350 on the native virus particle may enhance its
immunogenicity. Whereas UV-EBV (and the soluble re-
combinant protein) were produced in primate cells, the
chimeric VLP was produced in rodent cells, thus con-
tamination with xenogeneic antigen may have further
contributed to the enhanced immunogenicity of UV-
EBV; and the soluble recombinant protein may de facto
be less immunogenic than was scored herein. Further-
more antibody titers were detected using ELISA plates
coated with primate (293-derived) recombinant gp350/
220 – potentially amplifying the response of mice immu-
nized with UV-virus and recombinant protein on this
basis alone. We note that rather than enhancing immuno-
genicity as hypothesized, inclusion of the HR2 trimeriza-
tion domain from NDV-F in the ED of the chimera may
have contributed to some degree of misfolding and
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actually blunted the immune response to the chimeric
VLP – this is currently being addressed. The quantity of
gp350/220 ED expressed on the surface of VLPs can po-
tentially be manipulated to introduce more immunogen in
a more compact form that may enhance immunogenicity,
or simple addition of more chimeric VLPs may enhance
neutralizing antibody responses. Analogous to experi-
ments conducted with respiratory syncytial virus [35] a
further strength of this NDV platform is the potential to
accommodate other EBV proteins able to block entry or
initiation of infection upon introduction into a single
VLP or by immunization with a combination of VLPs
bearing different EBV chimeras, similar to VLP strat-
egies that prevent human papillomavirus infection and
associated cancers [52,53].
Conclusions
While many acute viral infections and two major virus-
associated malignancies have been reduced or eliminated
through vaccination, adverse consequences resulting from
EBV infection continue to emerge. Paradoxically, global
development leading to delayed primary EBV infection
has increased the incidence of AIM and with it a predis-
position to Hodgkin lymphoma and autoimmune disease.
In addition to prevention of EBV+ endemic malignancies,
increasing survival of a spectrum of immunocompromised
hosts susceptible to EBV+ lymphoproliferative diseases
(e.g. the elderly, transplant recipients, persons with HIV
or advanced autoimmune diseases) highlights a critical
need for an effective immunogen – that is an EBV vaccine
that is safe, prevents infection and/or limits the manifesta-
tions of disease. Herein we show that a simple innovative
NDV-VLP platform supports generation of abundant
chimeric EBVgp350/220-F VLPs devoid of oncogenic po-
tential. These VLPs are efficiently produced, released,
purified and quantified from CHO cells, a preferred re-
pository for human biologics. The VLPs are nontoxic and
stimulate production of long-lasting and neutralizing anti-
bodies in standard BALB/c mice. Particle optimization
and broad evaluation of immunologic properties in add-
itional animal models merit ongoing investigation of this
novel EBV vaccine candidate.
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